Regulation And Legal
FTC Orders Aurobindo Divest $250M Lannett Deal
FTC issued a consent order requiring Aurobindo Pharma to sell four drugs to Quagen as condition for its $250 million acquisition of Lannett.
The divested products include mycophenolate mofetil suspens
